Oncothyreon Inc. (ONTY) in Focus: Stock up 6.1% - Tale of the Tape

Oncothyreon Inc. ONTY was a big mover last session, as the company saw its shares rise slightly over 6% on the day. This jump can be attributable to solid volume too with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $2.83 to $3.89 in the past one-month time frame, showed a pick-up yesterday at $3.60.

The company has seen 2 positive revisions in the past month, while its Zacks Consensus Estimate, which is pegged at a loss, narrowed over the same period, suggesting that more solid trading could be ahead for Oncothyreon. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Oncothyreon currently has a Zacks Rank #2 (Buy) while its Earnings ESP is negative.

Some other players in the healthcare industry include Alexion Pharmaceuticals, Inc. ALXN, with a Zacks Rank #1 (Strong Buy) along with Actelion Ltd. (ALIOF) and Cambrex Corporation.CBM holding a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

ACTELION LTD (ALIOF): Get Free Report

ALEXION PHARMA ALXN: Free Stock Analysis Report

CAMBREX CORP CBM: Free Stock Analysis Report

ONCOTHYREON INC ONTY: Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Market News and Data brought to you by Benzinga APIs